Overview of the Molecular Characteristics of PYLARIFY

Videos — January 26, 2022

Featuring:

Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD

Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®.

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: